Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25904177 | 0.85 | CYP3A4 (0.37) | CYP3A4EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL25904083 | 0.81 | GPR119 (0.38) | CYP3A4EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL2195346 | 0.80 | GPR119 (0.53) | EPHX2GPR119NAMPT | |
| SCHEMBL9994188 | 0.80 | PLG (0.34) | CHRM2CHRM1CHRM3GPR119NAMPT | |
| SCHEMBL25730183 | 0.79 | OPRM1 (0.41) | EPHX2ALDH1A1OPRD1NAMPT | |
| SCHEMBL18701964 | 0.78 | EPHX2 (0.41) | CYP3A4EPHX2ALDH1A1HTTOPRD1 | |
| SCHEMBL29317699 | 0.78 | EPHX2 (0.39) | CYP3A4EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL23945976 | 0.78 | NAMPT (0.36) | CYP3A4EPHX2ALDH1A1HTTGPR119 | |
| SCHEMBL20439114 | 0.78 | CHRM2 (0.49) | CHRM2CHRM1CHRM3AOC2CNR2 | |
| SCHEMBL23696235 | 0.77 | L3MBTL1 (0.35) | ALDH1A1GPR119OPRD1NAMPTAOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP3A4 2542/4885EPHX2 1890/4885CHRM2 4681/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP3A4 2542/4885EPHX2 1890/4885CHRM2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.